GEO series

VHL loss reprograms the immune landscape to promote an inflammatory myeloid microenvironment in renal tumorigenesis

GSE239889 Mus musculus (mouse) RNA-seq (gene expression) 52 samples Submitted 2024/04/17 Platform GPL24676Platform GPL24247

At a glance

RNA-seq (gene expression) · mouse · 52 samples

What it is: RNA-seq (gene expression)Gene activity measured by sequencing. The summary does not mention single-cell work, so this is most likely bulk: one average per sample, the usual starting point for comparing groups.
Organism: Mus musculus (mouse)
Topic: Kidney cancerThis series is part of our curated briefing on it.
Samples: 52 samples
Data you can get: A processed table (series matrix) and supplementary files from NCBI; the raw sequencing reads from ENA. Which of these hold counts depends on the study, so check the file list.

Summary (written by the submitters)

Clear cell renal cell carcinoma (ccRCC) is an aggressive disease characterized by dysregulated hypoxia signaling, metabolic defects, and a complex tumor microenvironment (TME) highly enriched in lymphoid and myeloid immune cells. Loss of the oxygen sensing gene, von Hippel Lindau (VHL), is a critical early event in ccRCC pathogenesis and promotes stabilization of hypoxia inducible factors (HIF) that upregulate pro-growth signaling pathways, including angiogenesis and aerobic glycolysis.

Read the full summary ↓

However, whether VHL loss in cancer cells impacts the composition, metabolism, or function of immune cells in the TME remains unclear. Using Vhl wildtype (WT) and knockout (KO) in vivo murine kidney cancer models, we found that Vhl KO tumors were less proliferative and more infiltrated by immune cells. Tumor-associated macrophages (TAM) demonstrated enhanced proinflammatory transcriptional signatures from Vhl deficient tumors, and intratumoral myeloid cells residing in the Vhl KO TME showed increased in vivo glucose consumption. Vhl loss did not confer increased in vivo glucose uptake in cancer cells or lymphocytes, or detectable changes in metabolites in the interstitial fluid. Mechanistically, enhanced secretion of the chemokine, CX3CL1, was observed in Vhl KO cancer cells and its cognate receptor, CX3CR1, was significantly elevated on myeloid cells residing in the TME of Vhl deficient tumors. Human ccRCC tumors exhibit high expression of CX3CL1 and CX3CR1 as well as enhanced myeloid metabolism and proinflammatory properties. Here, we identify the importance of cancer cell-specific genetic features to drive environmental reprograming and shape the tumor immune landscape and identify a potential therapeutic target in the treatment of ccRCC.

This dataset

Open GSE239889 in finder → Find more RNA-seq datasets → Kidney cancer landscape →

Download · which file do I need?

Direct links to NCBI and ENA, no account and no request form. Pick by what you want to do: take the small processed table to look, the supplementary files to re-analyse, or the original raw data to start over.

1 · Just have a look

Processed table

The series matrix: one table of values per sample as the submitters processed it. The smallest download, and it opens in Excel or R. Start here to see what the data look like.

Series matrix ↓

2 · Re-analyse it

Supplementary files

The count tables and other files the authors uploaded. Take only the samples you need, or the whole study as GSE239889_RAW.tar (it can run to tens of gigabytes).

All supplementary files ↗ Whole study · RAW.tar ↓

3 · Start from the raw reads

Raw sequencing reads

The original FASTQ files, straight from the sequencer, held at ENA. Large, and you align them yourself, so only choose this if you need to re-process the study from scratch.

Raw reads on ENA ↗

What the files usually look like: For RNA-seq the counts are usually a table among the supplementary files (look for 'counts', 'expression', 'FPKM' or 'TPM' in the file name). The series matrix of a sequencing study is sometimes nearly empty.

Also filed as BioProject PRJNA1001347 and SRA study SRP452987. Searching any of these in the dataset finder brings you back here.

NCBI GEO page ↗

Samples in this study

The sample list for this study is not cached yet. Press Load samples and it will be fetched from NCBI.

+ 52 more — browse all 52 samples with per-sample file links →

More Kidney cancer datasets

GSE216495 Nonclinical in-vitro evaluation of the transcriptomic and metabolic effects of immune checkpoint inhibitors on sunitinib-resistant renal cell carcinoma 36 samples same disease briefing · shares renal
GSE216494 Impact of sunitinib resistance on clear cell renal cell carcinoma therapeutic sensitivity in vitro 12 samples same disease briefing · shares renal
GSE174740 Drug repurposing identifies a synergistic high-order drug combination to treat sunitinib-resistant renal cell carcinoma 11 samples same disease briefing · shares renal
GSE223688 SETD2 loss sensitizes kidney cancer cells to DNA hypomethylating agents 6 samples same disease briefing · shares loss
GSE193006 Transcriptome RNA sequencing data of sarcomatoid renal cell carcinoma cell line SRCC and its subclones with different phenotypes. 5 samples same disease briefing · shares renal
GSE15641 Gene signatures of progression and metastasis in renal cell cancer 92 samples same disease briefing · shares renal
GSE19982 Gene expression discriminates chromophobe renal cell carcinoma and oncocytoma 30 samples same disease briefing · shares renal
GSE214635 The E3 ligase RBCK1 reduces the sensitivity of ccRCC to sunitinib through the ANKRD35-MITD1-ANXA1 axis 18 samples same disease briefing

Search all RNA-seq datasets in GEO →

Share this dataset

Metadata from NCBI GEO, cached and refreshed periodically — the NCBI page above is authoritative. Downloads link straight to NCBI/ENA; nothing is proxied through BioTransfer.